@article{288debb3fef1481c87d8ce226e8abce9,
title = "Association of spermidine plasma levels with brain aging in a population-based study",
abstract = "Introduction: Supplementation with spermidine may support healthy aging, but elevated spermidine tissue levels were shown to be an indicator of Alzheimer's disease (AD). Methods: Data from 659 participants (age range: 21–81 years) of the population-based Study of Health in Pomerania TREND were included. We investigated the association between spermidine plasma levels and markers of brain aging (hippocampal volume, AD score, global cortical thickness [CT], and white matter hyperintensities [WMH]). Results: Higher spermidine levels were significantly associated with lower hippocampal volume ({\ss} = −0.076; 95% confidence interval [CI]: −0.13 to −0.02; q = 0.026), higher AD score ({\ss} = 0.118; 95% CI: 0.05 to 0.19; q = 0.006), lower global CT ({\ss} = −0.104; 95% CI: −0.17 to −0.04; q = 0.014), but not WMH volume. Sensitivity analysis revealed no substantial changes after excluding participants with cancer, depression, or hemolysis. Discussion: Elevated spermidine plasma levels are associated with advanced brain aging and might serve as potential early biomarker for AD and vascular brain pathology.",
keywords = "Alzheimer's disease, cortical thickness, epidemiology, hippocampal volume, spermidine, white matter hyperintensities",
author = "Wortha, {Silke M.} and Stefan Frenzel and Martin Bahls and Mohamad Habes and Katharina Wittfeld and {Van der Auwera}, Sandra and Robin B{\"u}low and Stephanie Zylla and Nele Friedrich and Matthias Nauck and Henry V{\"o}lzke and Grabe, {Hans J.} and Claudia Schwarz and Agnes Fl{\"o}el",
note = "Funding Information: H.J.G. has received travel grants and speakers{\textquoteright} honoraria from Fresenius Medical Care, Neuraxpharm, Servier, and Janssen Cilag as well as research funding from Fresenius Medical Care. A.F. has received consulting fees and speakers{\textquoteright} honoraria from Biogen, Roche, Novartis, and Bayer. All other authors declare no conflicts of interest. Author disclosures are available in the supporting information . Funding Information: SHIP is part of the Community Medicine Research net of the University of Greifswald, Germany, which is funded by the Federal Ministry of Education and Research (grants no. 01ZZ9603, 01ZZ0103, and 01ZZ0403), the Ministry of Cultural Affairs, and the Social Ministry of the Federal State of Mecklenburg‐West Pomerania. MRI scans in SHIP‐TREND have been supported by a joint grant from Siemens Healthineers, Erlangen, Germany, and the Federal State of Mecklenburg‐West Pomerania. This study was further supported by National Institutes of Health Grant RF1 AG059421. Moreover, this work was additionally supported by grants from the Deutsche Forschungsgemeinschaft (Fl 379‐16/1; Fl 379‐22/1, Fl 379‐30/1, and 327654276 ‐ SFB 1315) to AF. SV was supported by the Federal Ministry of Education and Research (BMBF, gr. No. 01KU2004) under the frame of ERA PerMed (TRAJECTOME project, ERAPERMED2019‐108). Finally, this study was supported in part by the National Institutes of Health (NIH) grant numbers 1R01AG080821, P30AG066546, 1U24AG074855, and the San Antonio Medical Foundation grant SAMF – 1000003860 to MH. Publisher Copyright: {\textcopyright} 2022 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.",
year = "2022",
doi = "10.1002/alz.12815",
language = "English (US)",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
publisher = "Elsevier Inc.",
}